BeiGene Shares Gap Up to 149.75 - MarketBeat
| B1GN34 Stock | BRL 42.30 1.46 3.34% |
About 61% of BeiGene's investor base is looking to short. The analysis of current outlook of investing in BeiGene suggests that many traders are alarmed regarding BeiGene's prospects. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
BeiGene Shares Gap Up to 149.75 MarketBeat
Read at news.google.com
 |
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
BeiGene is rated below average in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
| BIOM3 | Biomm SA | 6.74 | ||||
| N1VO34 | Novo Nordisk | 6.39 | ||||
| VRTX34 | Vertex Pharmaceuticals | 2.42 | ||||
| T1CH34 | Bio Techne | 1.31 | ||||
| B1NT34 | BIONTECH | 0.87 | ||||
| M1RN34 | Moderna | 0.41 | ||||
| A1SN34 | Ascendis Pharma | 0.00 | ||||
| B1GN34 | BeiGene | 3.34 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| CEOs Directory Screen CEOs from public companies around the world |